Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

17.33 +0.11 (+0.64%)
Streaming Delayed Price Updated: 3:38 PM EDT, Jun 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Teva Pharmaceutical Industries ADR

< Previous 1 2 3 4 5 6 7 Next >
Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society International Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bacterial Infections, in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Association Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reports First Quarter 2021 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clinical Outcomes at Upcoming 2021 American Psychiatric Association Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Launch of its Generic Version of Canasa® (mesalamine) Suppositories To Treat Adults with Active Ulcerative Proctitis (ulcerative rectal colitis), in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Reduction of Migraine Burden Presented at 2021 American Academy of Neurology Virtual Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at Upcoming 2021 American Academy of Neurology Virtual Annual Meeting, Highlighting Teva’s Ongoing Commitment to Neurology
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults
From Teva Pharmaceuticals Industries Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.